Back to results
US 2025/0082755 A1Published application
Chimeric antigen receptors for treatment of cancer
AssigneeVor Biopharma Inc.
InventorsRebecca Moeller, Tirtha Chakraborty, Julian Scherer
Life of this patent
Estimating the term…
Abstract
Provided herein are chimeric antigen receptors (CARs) with binding specificity for CD123. Nucleic acids, expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed, and methods including the treatment of a hematopoietic malignancy or premalignancy characterized by the expression of CD123, e.g., leukemias such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Claims49
A chimeric antigen receptor (CAR), comprising
- a. an interleukin-3 (IL-3) molecule or a CD123-binding fragment thereof;
- b. optionally, a linker region,
- c. optionally, a hinge region,
- d. a transmembrane region,
- e. optionally, at least one costimulatory signaling domain, and
- f. a signaling domain.
3 more elements
Dependencies are inferred from the claim text.